DEF: Microbot Medical Schedules 2026 Annual Meeting, Proposes Share Plan Increase

Microbot Medical Inc. has announced its 2026 Annual Meeting of Shareholders, scheduled for December 14, 2026, with key proposals including director elections, executive compensation advisory vote, and an increase in authorized shares for its 2020 Omnibus Performance Award Plan.

Summary

• Microbot Medical Inc. is holding its 2026 Annual Meeting of Shareholders on December 14, 2026, at 9:00 AM ET in Boston, MA.
• Shareholders will vote on the election of two Class II directors, an advisory resolution on executive compensation, an amendment to increase the 2020 Omnibus Performance Award Plan by 1,000,000 shares, and the ratification of the independent registered public accounting firm.
• The record date for determining eligible shareholders is October 15, 2026, with 67,164,801 shares of common stock outstanding.
• The company is seeking to increase its equity incentive pool to attract and retain talent, noting that approximately 1,416,923 shares remain available under the current plan.
• Detailed information on executive compensation, director compensation, and the company's Code of Business Conduct and Ethics is provided.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily focused on routine corporate governance and shareholder matters, with a key proposal for equity incentive plan expansion.

Positives

• The company is proactively managing its governance by holding its annual meeting and seeking shareholder approval for key items.
• The proposed increase in the Omnibus Performance Award Plan aims to support talent acquisition and retention, crucial for a growing company.
• The company maintains a clear process for shareholder proposals and director nominations, adhering to good corporate governance practices.
• All Section 16(a) filing requirements for officers, directors, and greater than 10% beneficial owners were met for the fiscal year ended December 31, 2025.

Negatives

• The company's financial performance is not detailed in this proxy statement, as it focuses on governance and compensation matters.
• The proposed increase in authorized shares for the equity plan will lead to additional potential dilution for existing shareholders.

Risks

• Failure to approve the amendment to the 2020 Omnibus Performance Award Plan could hinder the company's ability to grant equity awards, potentially impacting employee retention and recruitment.
• The potential dilution from the increased share reserve under the equity plan could negatively impact the value of existing shares if not offset by significant company growth and value creation.

Future Outlook

The filing does not contain specific forward-looking financial guidance. However, the proposed increase in the equity incentive plan suggests a focus on future growth and talent management.

Management Comments

• "Your vote is important to us."
• "The Board believes that the Amended Plan and the increase in the number of shares available for grant thereunder are important to allow us to continue to attract, motivate, reward and retain the talent critical to achieving our business goals."
• "Although this vote is non-binding, our Board and Compensation Committee value the opinions of our shareholders and will consider the outcome of this vote when making future compensation decisions affecting our executive officers."
• "The Board of Directors believes that asking stockholders to ratify the appointment of Deloitte, or its U.S. affiliate, is consistent with best practices in corporate governance."

Industry Context

StockSavvy.ai notes that the proposal to increase equity awards is common for companies in the medical device sector, particularly those in development or early commercialization stages, as it aids in attracting and retaining specialized talent without immediately depleting cash reserves.

Comparison to Industry Standards

• The proposed increase of 1,000,000 shares to the 2020 Omnibus Performance Award Plan represents approximately 1.5% of the current outstanding shares (67,164,801). This is a moderate increase compared to industry standards, where companies often seek increases of 3-5% of outstanding shares in their equity plans.
• The director compensation package, with a base of $40,000 per annum plus committee stipends, is generally in line with smaller to mid-cap companies in the technology and healthcare sectors.
• The executive compensation structure, heavily weighted towards stock options and bonuses, aligns with common practices aimed at incentivizing performance and aligning executive interests with shareholders.

Corporate Governance

Related Party Transactions

• There have been no related party transactions or other transactions/relationships required to be disclosed pursuant to Item 404 of Regulation S-K.

Stakeholder Impact

• Shareholders: Voting on director elections, executive compensation, and equity plan expansion. Potential dilution from equity plan increase.
• Employees: Potential for continued equity-based incentives to attract, motivate, and retain talent.
• Management: Subject to advisory vote on compensation; potential impact on future compensation decisions.
• Auditors: Continued engagement of Deloitte (or its U.S. affiliate) for the fiscal year ending December 31, 2026.

Next Steps

• Shareholders will vote on the proposed items at the 2026 Annual Meeting of Shareholders on December 14, 2026.
• The Board of Directors and Compensation Committee will consider shareholder feedback on executive compensation.
• If approved, the amendment to the 2020 Omnibus Performance Award Plan will increase the authorized shares by 1,000,000.
• The company will proceed with the engagement of Deloitte (or its U.S. affiliate) as its independent registered public accounting firm for the year ending December 31, 2026, subject to ratification.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new financial results or significant strategic shifts that would warrant a buy or sell recommendation. The proposals are standard corporate governance items. The equity plan increase is a positive for talent management but carries potential dilution. Therefore, a 'hold' recommendation is appropriate pending further material developments.

Keywords

Annual Meeting, Proxy Statement, Shareholder Vote, Equity Incentive Plan, Director Election, Executive Compensation, Stock Options, Corporate Governance